U.S. Diabetic Retinopathy Market Summary

The U.S. diabetic retinopathy market size was estimated at USD 3.02 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.3% from 2024 to 2030. This anticipated growth is driven by multiple key factors, including the expanding geriatric population, a surge in diabetes cases due to sedentary lifestyles and poor dietary habits, the increasing prevalence of obesity, and the high cost of treating the condition. In addition, the market is being positively influenced by the introduction and rising adoption of advanced technologies such as artificial intelligence (AI), data analytics, and smart diabetes management devices, all of which are contributing to better diagnosis and treatment outcomes.

Diabetic retinopathy is a serious complication that arises from both type I and type II diabetes. It impacts the tiny blood vessels located in the retina, and if not managed properly, can progressively deteriorate vision, eventually leading to blindness or other severe visual impairments. In the U.S., the number of individuals affected by diabetic retinopathy is expected to increase significantly, with projections indicating that one in every 29 people could suffer from the condition. This positions diabetic retinopathy as one of the top causes of blindness across the nation. Moreover, individuals diagnosed with diabetes are at heightened risk of developing additional diabetes-related eye disorders, including macular edema, cataracts, and glaucoma, further intensifying the need for early detection and effective treatment.

Key Market Trends & Insights

• In 2023, the Anti-VEGF segment accounted for the dominant share of the market, contributing 91.74% of the total revenue. Anti-VEGF (vascular endothelial growth factor) agents are administered through intraocular injections and function by inhibiting the formation of weak and abnormal blood vessels, thereby slowing the progression of diabetic retinopathy. Currently, four major anti-VEGF drugs—Eylea, Avastin, Lucentis, and Macugen—have received approval from the U.S. Food and Drug Administration (FDA). Market leaders are planning to introduce new anti-VEGF formulations during the forecast period with the goal of enhancing therapeutic efficacy, minimizing side effects, and accelerating patient recovery timelines.
• The non-proliferative diabetic retinopathy (NPDR) segment held the largest market share at 70.36% in 2023. This segment’s dominance is primarily due to the high number of diabetes patients with a disease history of less than ten years, which is typically when NPDR manifests. NPDR is considered the early stage of diabetic eye disease and progresses from mild to moderate severity before potentially advancing to more severe forms. Rising awareness regarding early diagnosis and the growing concern over diabetes-related visual complications are likely to support the continued expansion of this segment.
• Meanwhile, the proliferative diabetic retinopathy (PDR) segment is anticipated to experience the highest growth over the forecast period. PDR represents the advanced stage of diabetic retinopathy and often necessitates laser-based surgical interventions to seal or shrink the delicate and newly formed blood vessels in the retina. Emerging pharmaceutical innovations, the incorporation of cutting-edge diagnostic technologies, adoption of new treatment therapies, and ongoing improvements in the U.S. healthcare infrastructure are collectively expected to drive this segment’s robust expansion.

Order a free sample PDF of the U.S. Diabetic Retinopathy Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2023 Market Size: USD 3.02 billion
• 2030 Projected Market Size: USD 4.62 billion
• CAGR (2024 - 2030): 6.3%

Key Companies & Market Share Insights

Some prominent U.S. diabetic retinopathy market companies include Bayer AG, ABBVIE INC., Novartis AG, Oxurion NV, Sirnaomics, Alimera Sciences, Ampio Pharmaceuticals Inc., BCNPeptides, Kowa Company, Ltd., and Genentech, Inc. Key market players are focusing on innovative product launches, growth strategies, and technological advancements.

These players have strong distribution networks and their capacity to invest heavily in R&D efforts to launch tailored products is likely to offer a competitive edge. Brand preference in this market is high, considering the presence of these key players.

Key Players

• Bayer AG
• ABBVIE INC.
• Novartis AG
• Oxurion NV
• Sirnaomics
• Alimera Sciences
• Ampio Pharmaceuticals Inc.
• BCNPeptides
• Kowa Company Ltd.
• Genentech, Inc.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

In conclusion, the U.S. diabetic retinopathy market is witnessing sustained growth, supported by the increasing prevalence of diabetes, technological advancements, and rising healthcare awareness. The dominance of anti-VEGF therapies and the growing demand for early-stage diagnostic tools highlight the need for improved treatment strategies. While non-proliferative retinopathy accounts for a major market share, proliferative retinopathy is emerging rapidly due to advancements in therapy and diagnostics. As the aging population and obesity rates continue to rise, and with greater focus on innovative healthcare solutions, the diabetic retinopathy market is well-positioned for significant progress through the forecast period.